# Stephen Jolles

## List of Publications by Citations



| | | | |
|---|---|---|---|
| 154 papers | 4,764 citations | 39 h-index | 64 g-index |
| 176 ext. papers | 6,105 ext. citations | 5.2 avg, IF | 5.67 L-index |

| # | Paper | IF | Citations |
|---|---|---|---|
| 154 | Clinical uses of intravenous immunoglobulin. *Clinical and Experimental Immunology*, **2005**, 142, 1-11 | 6.2 | 221 |
| 153 | Primary immunodeficiency diseases: Genomic approaches delineate heterogeneous Mendelian disorders. *Journal of Allergy and Clinical Immunology*, **2017**, 139, 232-245 | 11.5 | 164 |
| 152 | The evolution of cellular deficiency in GATA2 mutation. *Blood*, **2014**, 123, 863-74 | 2.2 | 153 |
| 151 | Coronavirus disease 2019 in patients with inborn errors of immunity: An international study. *Journal of Allergy and Clinical Immunology*, **2021**, 147, 520-531 | 11.5 | 142 |
| 150 | Mutations in TRNT1 cause congenital sideroblastic anemia with immunodeficiency, fevers, and developmental delay (SIFD). *Blood*, **2014**, 124, 2867-71 | 2.2 | 134 |
| 149 | Dermatological uses of high-dose intravenous immunoglobulin. *Archives of Dermatology*, **1998**, 134, 80-6 | | 134 |
| 148 | Immunomodulatory action of intravenous immunoglobulin. *Immunology*, **2002**, 107, 387-93 | 7.8 | 129 |
| 147 | Clinical applications of intravenous immunoglobulins (IVIg)--beyond immunodeficiencies and neurology. *Clinical and Experimental Immunology*, **2009**, 158 Suppl 1, 23-33 | 6.2 | 100 |
| 146 | The FcRn inhibitor rozanolixizumab reduces human serum IgG concentration: A randomized phase 1 study. *Science Translational Medicine*, **2017**, 9, | 17.5 | 94 |
| 145 | Current treatment options with immunoglobulin G for the individualization of care in patients with primary immunodeficiency disease. *Clinical and Experimental Immunology*, **2015**, 179, 146-60 | 6.2 | 94 |
| 144 | Hematopoietic stem cell transplantation rescues the hematological, immunological, and vascular phenotype in DADA2. *Blood*, **2017**, 130, 2682-2688 | 2.2 | 93 |
| 143 | Efficacy and safety of Hizentra( ) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy. *Clinical Immunology*, **2011**, 141, 90-102 | 9 | 90 |
| 142 | Drug-induced aseptic meningitis: diagnosis and management. *Drug Safety*, **2000**, 22, 215-26 | 5.1 | 89 |
| 141 | Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase Syndrome Registry. *Frontiers in Immunology*, **2018**, 9, 543 | 8.4 | 88 |
| 140 | Evaluation of correlation between dose and clinical outcomes in subcutaneous immunoglobulin replacement therapy. *Clinical and Experimental Immunology*, **2012**, 169, 172-81 | 6.2 | 88 |
| 139 | The variable in common variable immunodeficiency: a disease of complex phenotypes. *Journal of Allergy and Clinical Immunology: in Practice*, **2013**, 1, 545-56; quiz 557 | 5.4 | 87 |
| 138 | British Lung Foundation/United Kingdom Primary Immunodeficiency Network Consensus Statement on the Definition, Diagnosis, and Management of Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders. *Journal of Allergy and Clinical Immunology: in Practice*, **2017**, 5, 938-945 | 5.4 | 86 |

| | | | |
|---|---|---|---|
| 137 | A novel syndrome of congenital sideroblastic anemia, B-cell immunodeficiency, periodic fevers, and developmental delay (SIFD). *Blood*, **2013**, 122, 112-23 | 2.2 | 83 |
| 136 | Scleromyxedema: response to high-dose intravenous immunoglobulin (hdIVIg). *Journal of the American Academy of Dermatology*, **2000**, 43, 403-8 | 4.5 | 76 |
| 135 | The United Kingdom Primary Immune Deficiency (UKPID) Registry: report of the first 4 yearsQ activity 2008-2012. *Clinical and Experimental Immunology*, **2014**, 175, 68-78 | 6.2 | 73 |
| 134 | Whole-genome sequencing of a sporadic primary immunodeficiency cohort. *Nature*, **2020**, 583, 90-95 | 50.4 | 69 |
| 133 | The Expanding Field of Secondary Antibody Deficiency: Causes, Diagnosis, and Management. *Frontiers in Immunology*, **2019**, 10, 33 | 8.4 | 66 |
| 132 | Therapeutic efficacy of high-dose intravenous immunoglobulin in Mycobacterium tuberculosis infection in mice. *Infection and Immunity*, **2005**, 73, 6101-9 | 3.7 | 66 |
| 131 | Bioavailability of IgG administered by the subcutaneous route. *Journal of Clinical Immunology*, **2013**, 33, 984-90 | 5.7 | 65 |
| 130 | When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach. *Clinical and Experimental Immunology*, **2017**, 188, 333-341 | 6.2 | 64 |
| 129 | Hematopoietic stem cell transplantation in 29 patients hemizygous for hypomorphic /NEMO mutations. *Blood*, **2017**, 130, 1456-1467 | 2.2 | 61 |
| 128 | A review of high-dose intravenous immunoglobulin (hdIVIg) in the treatment of the autoimmune blistering disorders. *Clinical and Experimental Dermatology*, **2001**, 26, 127-31 | 1.8 | 61 |
| 127 | A UK national audit of hereditary and acquired angioedema. *Clinical and Experimental Immunology*, **2014**, 175, 59-67 | 6.2 | 59 |
| 126 | The utility of the ISAC allergen array in the investigation of idiopathic anaphylaxis. *Clinical and Experimental Immunology*, **2014**, 177, 483-90 | 6.2 | 56 |
| 125 | Clinical relevance of differential lymphocyte recovery after alemtuzumab therapy for multiple sclerosis. *Neurology*, **2013**, 80, 55-61 | 6.5 | 53 |
| 124 | The treatment of atopic dermatitis with adjunctive high-dose intravenous immunoglobulin: a report of three patients and review of the literature. *British Journal of Dermatology*, **2000**, 142, 551-4 | 4 | 52 |
| 123 | Impaired T(H)17 responses in patients with chronic mucocutaneous candidiasis with and without autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. *Journal of Allergy and Clinical Immunology*, **2010**, 126, 1006-15, 1015.e1-4 | 11.5 | 50 |
| 122 | Secondary antibody deficiency: a complication of anti-CD20 therapy for neuroinflammation. *Journal of Neurology*, **2018**, 265, 1115-1122 | 5.5 | 48 |
| 121 | The Lung in Primary Immunodeficiencies: New Concepts in Infection and Inflammation. *Frontiers in Immunology*, **2018**, 9, 1837 | 8.4 | 42 |
| 120 | Chronic granulomatous disease caused by mutations other than the common GT deletion in NCF1, the gene encoding the p47phox component of the phagocyte NADPH oxidase. *Human Mutation*, **2006**, 27, 1218-29 | 4.7 | 41 |

| | | | |
|---|---|---|---|
| 119 | A review of high-dose intravenous immunoglobulin treatment for atopic dermatitis. *Clinical and Experimental Dermatology*, **2002**, 27, 3-7 | 1.8 | 41 |
| 118 | Efficacy and safety of hizentra , a new 20% immunoglobulin preparation for subcutaneous administration, in pediatric patients with primary immunodeficiency. *Journal of Clinical Immunology*, **2011**, 31, 752-61 | 5.7 | 40 |
| 117 | Use of IGIV in the treatment of atopic dermatitis, urticaria, scleromyxedema, pyoderma gangrenosum, psoriasis, and pretibial myxedema. *International Immunopharmacology*, **2006**, 6, 579-91 | 5.8 | 40 |
| 116 | Adjunctive high-dose intravenous immunoglobulin treatment for resistant atopic dermatitis: efficacy and effects on intracellular cytokine levels and CD4 counts. *Acta Dermato-Venereologica*, **2003**, 83, 433-7 | 2.2 | 39 |
| 115 | Rituximab in neurological disease: principles, evidence and practice. *Practical Neurology*, **2019**, 19, 5-20 | 2.4 | 38 |
| 114 | FDG PET-CT imaging of therapeutic response in granulomatous lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID). *Clinical and Experimental Immunology*, **2017**, 187, 138-145 | 6.2 | 37 |
| 113 | Drug-induced aseptic meningitis. *Expert Opinion on Drug Safety*, **2005**, 4, 285-97 | 4.1 | 36 |
| 112 | Calculated globulin (CG) as a screening test for antibody deficiency. *Clinical and Experimental Immunology*, **2014**, 177, 671-8 | 6.2 | 35 |
| 111 | COVID-19 Vaccine Response in People with Multiple Sclerosis. *Annals of Neurology*, **2021**, 91, 89 | 9.4 | 35 |
| 110 | The United Kingdom Primary Immune Deficiency (UKPID) registry 2012 to 2017. *Clinical and Experimental Immunology*, **2018**, 192, 284-291 | 6.2 | 34 |
| 109 | Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach. *Advances in Therapy*, **2011**, 28, 521-33 | 4.1 | 32 |
| 108 | High-dose intravenous immunoglobulin (hdIVIg) in the treatment of autoimmune blistering disorders. *Clinical and Experimental Immunology*, **2002**, 129, 385-9 | 6.2 | 31 |
| 107 | Evaluation of a novel automated allergy microarray platform compared with three other allergy test methods. *Clinical and Experimental Immunology*, **2016**, 184, 1-10 | 6.2 | 30 |
| 106 | European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology. *Journal of the European Academy of Dermatology and Venereology*, **2016**, 30, 1657-1669 | 4.6 | 29 |
| 105 | Current strategies in TB immunotherapy. *Current Molecular Medicine*, **2007**, 7, 373-86 | 2.5 | 28 |
| 104 | International Consensus on the Use of Genetics in the Management of Hereditary Angioedema. *Journal of Allergy and Clinical Immunology: in Practice*, **2020**, 8, 901-911 | 5.4 | 28 |
| 103 | Phase 2 multiple-dose study of an FcRn inhibitor, rozanolixizumab, in patients with primary immune thrombocytopenia. *Blood Advances*, **2020**, 4, 4136-4146 | 7.8 | 28 |
| 102 | Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies. *Clinical and Experimental Immunology*, **2017**, 187, 146-159 | 6.2 | 27 |

| | | | |
|---|---|---|---|
| 101 | Intracellular interleukin-4 profiles during high-dose intravenous immunoglobulin treatment of therapy-resistant atopic dermatitis. *Journal of the American Academy of Dermatology*, **1999**, 40, 121-3 | 4.5 | 27 |
| 100 | Clinical and laboratory features of seventy-eight UK patients with Good syndrome (thymoma and hypogammaglobulinaemia). *Clinical and Experimental Immunology*, **2019**, 195, 132-138 | 6.2 | 27 |
| 99 | Clozapine is associated with secondary antibody deficiency. *British Journal of Psychiatry*, **2018**, 1-7 | 5.4 | 27 |
| 98 | C1 inhibitor deficiency: 2014 United Kingdom consensus document. *Clinical and Experimental Immunology*, **2015**, 180, 475-83 | 6.2 | 26 |
| 97 | Therapeutic failure of high-dose intravenous immunoglobulin in pemphigus vulgaris. *Journal of the American Academy of Dermatology*, **1999**, 40, 499-500 | 4.5 | 25 |
| 96 | Complement Inhibition with the C5 Blocker LFG316 in Severe COVID-19. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 202, 1304-1308 | 10.2 | 25 |
| 95 | European Society for Immunodeficiencies (ESID) and European Reference Network on Rare Primary Immunodeficiency, Autoinflammatory and Autoimmune Diseases (ERN RITA) Complement Guideline: Deficiencies, Diagnosis, and Management. *Journal of Clinical Immunology*, **2020**, 40, 576-591 | 5.7 | 23 |
| 94 | Long-term efficacy, safety, and tolerability of Hizentra for treatment of primary immunodeficiency disease. *Clinical Immunology*, **2014**, 150, 161-9 | 9 | 23 |
| 93 | Beneficial effect of anti-interleukin-4 antibody when administered in a murine model of tuberculosis infection. *Tuberculosis*, **2008**, 88, 197-202 | 2.6 | 23 |
| 92 | Facilitated subcutaneous immunoglobulin (fSCIg) therapy--practical considerations. *Clinical and Experimental Immunology*, **2015**, 182, 302-13 | 6.2 | 22 |
| 91 | Clinical immunology review series: an approach to the use of the immunology laboratory in the diagnosis of clinical allergy. *Clinical and Experimental Immunology*, **2008**, 153, 10-8 | 6.2 | 22 |
| 90 | Management of aseptic meningitis secondary to intravenous immunoglobulin **1998**, 316, 936-936 | | 22 |
| 89 | Using calculated globulin fraction to reduce diagnostic delay in primary and secondary hypogammaglobulinaemias: results of a demonstration project. *Annals of Clinical Biochemistry*, **2015**, 52, 319-26 | 2.2 | 21 |
| 88 | Measurement of Typhi Vi antibodies can be used to assess adaptive immunity in patients with immunodeficiency. *Clinical and Experimental Immunology*, **2018**, 192, 292-301 | 6.2 | 19 |
| 87 | Bronchiectasis and deteriorating lung function in agammaglobulinaemia despite immunoglobulin replacement therapy. *Clinical and Experimental Immunology*, **2018**, 191, 212-219 | 6.2 | 19 |
| 86 | Response of refractory immune thrombocytopenic purpura in a patient with common variable immunodeficiency to treatment with rituximab. *Journal of Clinical Pathology*, **2007**, 60, 715-6 | 3.9 | 19 |
| 85 | Autoinflammation due to homozygous S208 mutation. *Annals of the Rheumatic Diseases*, **2019**, 78, 571-573 | 14 | 19 |
| 84 | Clinical and laboratory correlates of lung disease and cancer in adults with idiopathic hypogammaglobulinaemia. *Clinical and Experimental Immunology*, **2016**, 184, 73-82 | 6.2 | 18 |

| | | | |
|---|---|---|---|
| 83 | Clinical immunology review series: an approach to the patient with anaphylaxis. *Clinical and Experimental Immunology*, **2008**, 153, 1-9 | 6.2 | 18 |
| 82 | Intravenous immunoglobulins. Current understanding and future directions. *Clinical and Experimental Immunology*, **2009**, 158 Suppl 1, 68-70 | 6.2 | 16 |
| 81 | Targeting FcRn for immunomodulation: Benefits, risks, and practical considerations. *Journal of Allergy and Clinical Immunology*, **2020**, 146, 479-491.e5 | 11.5 | 16 |
| 80 | Self-administered hyaluronidase-facilitated subcutaneous immunoglobulin home therapy in a patient with primary immunodeficiency. *Journal of Clinical Pathology*, **2010**, 63, 846-7 | 3.9 | 15 |
| 79 | Atypical C-ANCA following high dose intravenous immunoglobulin. *Journal of Clinical Pathology*, **1999**, 52, 177-80 | 3.9 | 15 |
| 78 | Human NK cell deficiency as a result of biallelic mutations in MCM10. *Journal of Clinical Investigation*, **2020**, 130, 5272-5286 | 15.9 | 15 |
| 77 | Anti-tumour necrosis factor treatment for the prevention of ischaemic events in patients with deficiency of adenosine deaminase 2 (DADA2). *Rheumatology*, **2021**, 60, 4373-4378 | 3.9 | 15 |
| 76 | European Guidelines (S1) on the use of high-dose intravenous immunoglobulin in dermatology. *JDDG - Journal of the German Society of Dermatology*, **2017**, 15, 228-241 | 1.2 | 14 |
| 75 | Screening protocols to monitor respiratory status in primary immunodeficiency disease: findings from a European survey and subclinical infection working group. *Clinical and Experimental Immunology*, **2017**, 190, 226-234 | 6.2 | 14 |
| 74 | Asymptomatic choroidal granulomas in common variable immunodeficiency. *Clinical and Experimental Ophthalmology*, **2005**, 33, 663-4 | 2.4 | 14 |
| 73 | Current screening approaches for antibody deficiency. *Current Opinion in Allergy and Clinical Immunology*, **2015**, 15, 547-55 | 3.3 | 13 |
| 72 | Systemic treatment with anti-CD40 antibody stimulates Langerhans cell migration from the skin. *Clinical and Experimental Immunology*, **2002**, 129, 519-26 | 6.2 | 13 |
| 71 | Development of a high-throughput SARS-CoV-2 antibody testing pathway using dried blood spot specimens. *Annals of Clinical Biochemistry*, **2021**, 58, 123-131 | 2.2 | 13 |
| 70 | Immunoglobulins: current understanding and future directions. *Clinical and Experimental Immunology*, **2014**, 178 Suppl 1, 163-8 | 6.2 | 12 |
| 69 | New Frontiers in Subcutaneous Immunoglobulin Treatment. *Biologics in Therapy*, **2011**, 1, 3 | | 12 |
| 68 | Clozapine-associated secondary antibody deficiency. *Current Opinion in Allergy and Clinical Immunology*, **2019**, 19, 553-562 | 3.3 | 12 |
| 67 | Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency. *ImmunoTargets and Therapy*, **2013**, 2, 125-33 | 9 | 11 |
| 66 | Current clinical uses of intravenous immunoglobulin. *Clinical Medicine*, **2006**, 6, 356-9 | 1.9 | 11 |

| | | | |
|---|---|---|---|
| 65 | New insights in the use of immunoglobulins for the management of immune deficiency (PID) patients. *American Journal of Clinical and Experimental Immunology*, **2017**, 6, 76-83 | 1.2 | 11 |
| 64 | Long-Term Efficacy and Safety of Hizentra in Patients with Primary Immunodeficiency in Japan, Europe, and the United States: a Review of 7 Phase 3 Trials. *Journal of Clinical Immunology*, **2018**, 38, 864-875 | 5.7 | 11 |
| 63 | Treatment Satisfaction with Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency: a Pooled Analysis of Six Hizentra Studies. *Journal of Clinical Immunology*, **2018**, 38, 886-897 | 5.7 | 11 |
| 62 | Subclinical infection and dosing in primary immunodeficiencies. *Clinical and Experimental Immunology*, **2014**, 178 Suppl 1, 67-9 | 6.2 | 10 |
| 61 | A recipient of immunoglobulin from a donor who developed vCJD. *Vox Sanguinis*, **2009**, 96, 270 | 3.1 | 10 |
| 60 | Intravenous immunoglobulin and autoimmune disease. *Annals of the New York Academy of Sciences*, **2007**, 1110, 507-15 | 6.5 | 10 |
| 59 | Global immunoglobulin supply: steaming towards the iceberg?. *Current Opinion in Allergy and Clinical Immunology*, **2020**, 20, 557-564 | 3.3 | 10 |
| 58 | Novel STAT1 Gain-of-Function Mutation Presenting as Combined Immunodeficiency. *Journal of Clinical Immunology*, **2018**, 38, 753-756 | 5.7 | 10 |
| 57 | Measurement and interpretation of Salmonella typhi Vi IgG antibodies for the assessment of adaptive immunity. *Journal of Immunological Methods*, **2018**, 459, 1-10 | 2.5 | 10 |
| 56 | Validation of Calculated Globulin (CG) as a Screening Test for Antibody Deficiency in an Italian University Hospital. *Current Pharmaceutical Biotechnology*, **2018**, 19, 728-733 | 2.6 | 9 |
| 55 | International retrospective study of allogeneic hematopoietic cell transplantation for activated PI3K-delta syndrome. *Journal of Allergy and Clinical Immunology*, **2021**, | 11.5 | 9 |
| 54 | Treatment of chronic or relapsing COVID-19 in immunodeficiency. *Journal of Allergy and Clinical Immunology*, **2021**, | 11.5 | 8 |
| 53 | Increased Respiratory Viral Detection and Symptom Burden Among Patients with Primary Antibody Deficiency: Results from the BIPAD Study. *Journal of Allergy and Clinical Immunology: in Practice*, **2021**, 9, 735-744.e6 | 5.4 | 8 |
| 52 | COVID-19 and X-linked agammaglobulinemia (XLA) - insights from a monogenic antibody deficiency. *Current Opinion in Allergy and Clinical Immunology*, **2021**, 21, 525-534 | 3.3 | 8 |
| 51 | Evaluation of the Safety, Tolerability, and Pharmacokinetics of Gammaplex 10% Versus Gammaplex 5% in Subjects with Primary Immunodeficiency. *Journal of Clinical Immunology*, **2017**, 37, 301-310 | 5.7 | 7 |
| 50 | Meningococcal meningitis in two patients with primary antibody deficiency treated with replacement intravenous immunoglobulin. *Journal of Clinical Pathology*, **2006**, 59, 1191-3 | 3.9 | 7 |
| 49 | Hematopoietic Cell Transplantation Cures Adenosine Deaminase 2 Deficiency: Report on 30 Patients. *Journal of Clinical Immunology*, **2021**, 41, 1633-1647 | 5.7 | 7 |
| 48 | Treating secondary antibody deficiency in patients with haematological malignancy: European expert consensus. *European Journal of Haematology*, **2021**, 106, 439-449 | 3.8 | 7 |

| | | | |
|---|---|---|---|
| 47 | Five years of self-administered hyaluronidase facilitated subcutaneous immunoglobulin (fSCIg) home therapy in a patient with primary immunodeficiency. *Journal of Clinical Pathology*, **2016**, 69, 87-8 | 3.9 | 6 |
| 46 | Population pharmacokinetic modeling and simulation of immunoglobulin exposure with varying dosing intervals of subcutaneous immunoglobulin 20% (Ig20Gly) in patients with primary immunodeficiency diseases. *International Immunopharmacology*, **2019**, 71, 404-410 | 5.8 | 6 |
| 45 | British Society for Immunology/United Kingdom Primary Immunodeficiency Network consensus statement on managing non-infectious complications of common variable immunodeficiency disorders. *Clinical and Experimental Immunology*, **2019**, 196, 328-335 | 6.2 | 6 |
| 44 | Managing Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders: e-GLILDnet International Clinicians Survey. *Frontiers in Immunology*, **2020**, 11, 606333 | 8.4 | 5 |
| 43 | Phenotypic and Functional Comparison of Class Switch Recombination Deficiencies with a Subgroup of Common Variable Immunodeficiencies. *Journal of Clinical Immunology*, **2016**, 36, 656-66 | 5.7 | 5 |
| 42 | Chronic norovirus infection in primary immune deficiency disorders: an international case series. *Diagnostic Microbiology and Infectious Disease*, **2019**, 93, 69-73 | 2.9 | 5 |
| 41 | Persistent SARS-CoV-2 infection: the urgent need for access to treatment and trials. *Lancet Infectious Diseases, The*, **2021**, 21, 1345-1347 | 25.5 | 5 |
| 40 | Quantification of human complement C2 protein using an automated turbidimetric immunoassay. *Clinical Chemistry and Laboratory Medicine*, **2018**, 56, 1498-1506 | 5.9 | 4 |
| 39 | Quantification of human C1 esterase inhibitor protein using an automated turbidimetric immunoassay. *Journal of Clinical Laboratory Analysis*, **2019**, 33, e22627 | 3 | 4 |
| 38 | Assessment of Local Adverse Reactions to Subcutaneous Immunoglobulin (SCIG) in Clinical Trials. *Journal of Clinical Immunology*, **2017**, 37, 517-518 | 5.7 | 4 |
| 37 | Skin Necrosis Following Subcutaneous Immunoglobulin (SCIg). *Journal of Clinical Immunology*, **2017**, 37, 27-28 | 5.7 | 4 |
| 36 | Importance of trial design in studies using high-dose intravenous immunoglobulin. *British Journal of Dermatology*, **2003**, 148, 1284-5; author reply 1285-6 | 4 | 4 |
| 35 | Rozanolixizumab, an Anti-FcRn Antibody: Final Results from a Phase II, Multiple-Dose Study in Patients with Primary Immune Thrombocytopenia. *Blood*, **2019**, 134, 897-897 | 2.2 | 4 |
| 34 | Burden of nosocomial COVID-19 in Wales: results from a multicentre retrospective observational study of 2508 hospitalised adults. *Thorax*, **2021**, 76, 1246-1249 | 7.3 | 4 |
| 33 | Long-term outcomes for adults with chronic granulomatous disease in the United Kingdom. *Journal of Allergy and Clinical Immunology*, **2021**, 147, 1104-1107 | 11.5 | 4 |
| 32 | Hematopoietic Stem Cell Transplantation Resolves the Immune Deficit Associated with STAT3-Dominant-Negative Hyper-IgE Syndrome. *Journal of Clinical Immunology*, **2021**, 41, 934-943 | 5.7 | 4 |
| 31 | Secondary antibody deficiency in neurology. *Current Opinion in Allergy and Clinical Immunology*, **2018**, 18, 481-488 | 3.3 | 4 |
| 30 | Europ□sche Leitlinien (S1) f□ die Anwendung von hochdosierten intraven□sen Immunglobulinen in der Dermatologie. *JDDG - Journal of the German Society of Dermatology*, **2017**, 15, 227-238 | 1.2 | 3 |

| | | | |
|---|---|---|---|
| 29 | The Construction of a Pharmacokinetic Model to Describe Intravenous and Subcutaneous Supplementation of IgG in Patients with Primary Immunodeficiency (PID). *Journal of Allergy and Clinical Immunology*, **2011**, 127, AB16-AB16 | 11.5 | 3 |
| 28 | Patients with anaphylaxis in accident and emergency are not referred to specialised allergy services. *Journal of Clinical Pathology*, **2010**, 63, 375 | 3.9 | 3 |
| 27 | Persistent COVID-19 Infection in Wiskott-Aldrich Syndrome Cleared Following Therapeutic Vaccination: a Case Report. *Journal of Clinical Immunology*, **2021**, 42, 32 | 5.7 | 3 |
| 26 | Antibody deficiency in patients taking clozapine. *BMJ, The*, **2019**, 364, l483 | 5.9 | 2 |
| 25 | Fatigue Symptoms Associated With COVID-19 in Convalescent or Recovered COVID-19 Patients; a Systematic Review and Meta-Analysis. *Annals of Behavioral Medicine*, **2021**, | 4.5 | 2 |
| 24 | Whole genome sequencing of a sporadic primary immunodeficiency cohort | | 2 |
| 23 | Mechanically ventilated patients shed high titre live SARS-CoV2 for extended periods from both the upper and lower respiratory tract.. *Clinical Infectious Diseases*, **2022**, | 11.6 | 2 |
| 22 | Improved anaphylaxis referral rates to specialized services from an Emergency Department. *Clinical and Experimental Allergy*, **2020**, 50, 973-976 | 4.1 | 1 |
| 21 | Safety and tolerability of subcutaneous immunoglobulin 20% in primary immunodeficiency diseases from two continents. *Immunotherapy*, **2019**, 11, 1057-1065 | 3.8 | 1 |
| 20 | Cytotoxic T-cell lymphoma complicating common variable immunodeficiency. *Pathology*, **2011**, 43, 75-8 | 1.6 | 1 |
| 19 | Periodic fever syndromes. *Paediatrics and Child Health (United Kingdom)*, **2010**, 20, 503-508 | 0.6 | 1 |
| 18 | Nuclear factor-B is not essential for NADPH oxidase activity in neutrophils from anhidrotic ectodermal dysplasia patients. *Blood*, **2009**, 113, 5362-5363 | 2.2 | 1 |
| 17 | The role of complement testing in dermatology. *Clinical and Experimental Dermatology*, **2005**, 30, 321-6 | 1.8 | 1 |
| 16 | Risk factors for severe infections in secondary immunodeficiency: a retrospective US administrative claims study in patients with hematological malignancies. *Leukemia and Lymphoma*, **2021**, 1-10 | 1.9 | 1 |
| 15 | Human NK cell deficiency as a result of biallelic mutations in MCM10 | | 1 |
| 14 | Haematopoietic Stem Cell Transplant for Norovirus-Induced Intestinal Failure in X-linked Agammaglobulinemia. *Journal of Clinical Immunology*, **2021**, 41, 1574-1581 | 5.7 | 1 |
| 13 | Medical algorithm: Diagnosis and management of antibody immunodeficiencies. *Allergy: European Journal of Allergy and Clinical Immunology*, **2021**, 76, 3841-3844 | 9.3 | 1 |
| 12 | Examining the utility of extended laboratory panel testing in the emergency department for risk stratification of patients with COVID-19: a single-centre retrospective service evaluation. *Journal of Clinical Pathology*, **2021**, | 3.9 | 1 |

| | | | |
|---|---|---|---|
| 11 | Serum Protein Electrophoresis May Be Used as a Screening Tool for Antibody Deficiency in Children and Adolescents. *Frontiers in Immunology*, **2021**, 12, 712637 | 8.4 | 1 |
| 10 | The burden of nosocomial covid-19: results from the Wales multi-centre retrospective observational study of 2518 hospitalised adults | | 1 |
| 9 | Clinical Outcome and Underlying Genetic Cause of Functional Terminal Complement Pathway Deficiencies in a Multicenter UK Cohort.. *Journal of Clinical Immunology*, **2022**, 1 | 5.7 | 0 |
| 8 | COVID-19 Vaccine Uptake and Efficacy in a National Immunodeficiency Cohort.. *Journal of Clinical Immunology*, **2022**, 1 | 5.7 | 0 |
| 7 | Subcutaneous Gammanorm by pump or rapid push infusion: Impact of the device on quality of life in adult patients with primary immunodeficiencies.. *Clinical Immunology*, **2022**, 236, 108938 | 9 | 0 |
| 6 | Heterozygous variants in ZBTB7A cause a neurodevelopmental disorder associated with symptomatic overgrowth of pharyngeal lymphoid tissue, macrocephaly, and elevated fetal hemoglobin. *American Journal of Medical Genetics, Part A*, **2021**, | 2.5 | 0 |
| 5 | Antibody Deficiency, Chronic Lung Disease, and Comorbid Conditions: A Case-Based Approach. *Journal of Allergy and Clinical Immunology: in Practice*, **2021**, 9, 3899-3908 | 5.4 | 0 |
| 4 | Infections in secondary immunodeficiency patients treated with Privigen or Hizentra: a retrospective US administrative claims study in patients with hematological malignancies. *Leukemia and Lymphoma*, **2021**, 1-11 | 1.9 | 0 |
| 3 | Case Report: Generalised Panniculitis as a Post-COVID-19 Presentation in Aicardi-Goutières Syndrome Treated With Ruxolitinib.. *Frontiers in Pediatrics*, **2022**, 10, 837568 | 3.4 | 0 |
| 2 | 7th International Immunoglobulin Conference: Foreword. *Clinical and Experimental Immunology*, **2014**, 178 Suppl 1, 1-2 | 6.2 | |
| 1 | Genomic Characterization of a Pediatric Cohort with Non-Malignant Lymphoproliferative Disorders. *Blood*, **2019**, 134, 83-83 | 2.2 | |